Pediatric Epilepsy Insurance Denied: Epidiolex, Ketogenic Diet, and VNS Appeals

Epilepsy affects approximately 470,000 children in the United States, and for many, seizures are not controlled with standard antiseizure medications. Drug-resistant epilepsy — defined by the International League Against Epilepsy (ILAE) as failure of two appropriately chosen antiseizure drug trials — affects approximately one-third of people with epilepsy. For these children, advanced treatments such as Epidiolex, the ketogenic diet, vagus nerve stimulation (VNS), and surgical evaluation at Level IV epilepsy centers are not optional — they are the next appropriate step in evidence-based care.

Epidiolex (Cannabidiol) Prior Authorization Denied: How to Appeal" class="auto-link">Prior Authorization

Epidiolex is a pharmaceutical-grade cannabidiol (CBD) product approved by the FDA in 2018 for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, and tuberous sclerosis complex. It is the first FDA-approved drug derived from cannabis.

Despite FDA approval, Epidiolex is frequently subject to prior authorization and step therapy requirements that create barriers to access. Common denial reasons include:

• The child has not met the required step therapy trials of other antiseizure medications
• The diagnosis (LGS, Dravet syndrome, TSC) is not confirmed by the insurer's criteria
• The drug is classified as high-tier formulary and the insurer requires an alternative

To appeal an Epidiolex denial:

1. Confirm that the diagnosis is documented by a neurologist and matches an FDA-approved indication (LGS, Dravet syndrome, or TSC)
2. Document the specific antiseizure medications tried and failed, with dosing and duration, to demonstrate drug resistance
3. Cite the ILAE definition of drug-resistant epilepsy (failure of two adequate trials) as the clinical threshold
4. Obtain a letter from the treating neurologist or epileptologist supporting the medical necessity of Epidiolex over additional failed drug trials
5. For Medicaid/CHIP enrollees, invoke EPSDT

Ketogenic Diet as Medical Treatment

The ketogenic diet (KD) is a high-fat, low-carbohydrate diet that has been used to treat drug-resistant epilepsy since the 1920s. It has Level I evidence supporting its effectiveness in children with drug-resistant epilepsy and is endorsed by the American Epilepsy Society.

The KD is considered a medical food therapy when administered under medical supervision, and its implementation requires:

• Evaluation and initiation by a specialized KD team (neurologist, dietitian, and often a metabolic dietitian)
• Prescription of specific medical formula products to maintain the diet
• Regular monitoring by the medical team

Insurance denials for ketogenic diet therapy most often target medical formula products and dietitian services. Coverage of medical formulas varies significantly by state and plan.

Several states have enacted medical food coverage laws that require insurers to cover formulas and food products prescribed as medical treatment. Review your state's medical food mandates. For Medicaid enrollees, EPSDT requires coverage of the ketogenic diet as medically necessary treatment for drug-resistant epilepsy in children under 21.

Vagus Nerve Stimulation Device

The vagus nerve stimulator (VNS) is an implanted device that delivers electrical impulses to the brain via the vagus nerve, reducing seizure frequency and severity. The FDA has approved VNS therapy for children as young as 4 years old with drug-resistant epilepsy.

VNS device denials typically involve:

• Determination that the child has not had enough antiseizure drug trials
• Classification of VNS as "experimental" (incorrect: VNS has been FDA-approved since 1997)
• Prior authorization requirements with criteria that exceed evidence-based standards

To appeal a VNS denial, cite the FDA approval, American Epilepsy Society guidelines supporting VNS in drug-resistant epilepsy, and the documented history of antiseizure drug failures. Include a letter from the treating epileptologist specifically recommending VNS.

Level IV Epilepsy Center Surgical Evaluation

Level IV epilepsy centers are the highest-level facilities in the National Association of Epilepsy Centers (NAEC) classification system. They are equipped to perform comprehensive epilepsy surgical evaluations, including video-EEG monitoring, intracranial electrode placement, and surgical resection of seizure foci.

Surgical evaluation and treatment at a Level IV center is appropriate — and potentially curative — for many children with drug-resistant focal epilepsy. Insurers sometimes deny referrals to these centers or deny coverage for the comprehensive presurgical evaluation, which can cost $20,000 to $50,000 or more.

Appeal strategies for Level IV epilepsy center denials:

• Document ILAE drug-resistance criteria (two failed drug trials)
• Cite NAEC and AES guidelines supporting surgical evaluation for drug-resistant focal epilepsy
• Argue network adequacy: if no in-network center has Level IV surgical capabilities, the insurer must provide an exception
• For Medicaid/CHIP: EPSDT covers the full presurgical evaluation as medically necessary

Fight Back With ClaimBack

Children with drug-resistant epilepsy are running out of time with every uncontrolled seizure. Insurance denials for established, evidence-based treatments are unjust and reversible. ClaimBack helps families build urgent appeals for epilepsy care denials.

Start your pediatric epilepsy appeal at ClaimBack

Related Reading

• What Is Medical Necessity?
• How to Write an Insurance Appeal Letter
• Internal vs. External Insurance Appeal: Which Should You File?